Universal Screening with a Glucose Challenge Test to Predict Gestational Diabetes Mellitus in a Diverse Population: A Retrospective Cohort Study

Gestational diabetes mellitus (GDM) is associated with significant maternal and neonatal morbidity. Screening strategies vary internationally and the diagnostic performance of the 50g glucose challenge test (50g GCT) as a universal screening tool remains uncertain across diverse populations. This retrospective cohort study included 18,213 singleton pregnancies at a London tertiary hospital between 2010 and 2023. Women routinely underwent the universal two-step GDM screening pathway: a 50g GCT at 24 - 32 weeks' gestation, followed by a diagnostic 75-g oral glucose tolerance test if the 50g GCT result was greater than or equal to 7.8 mmol/L. We evaluated the use of universal two-step screening in detecting GDM, how its prevalence varies with maternal characteristics, including ethnicity, body mass index, age, and in those who would not have been included in risk factor-indicated screening, and the association between the 50g GCT and adverse outcomes. 2,015 women had an abnormal GCT, and 406 (20.1%) had an abnormal 75g OGTT, with GDM diagnosed at 24-28 weeks. We also found 87 women, despite a normal GCT and/or normal OGTT, developed late-onset GDM. The overall prevalence of GDM was 4.4% (810/18,213). Universal screening will therefore identify a significant number of GDM cases, notably including those in a low-risk cohort who would not have been screened using a risk factor-based approach. When we examined glucose as a continuous variable, there was an association between increasing 50g GCT values and adverse maternal and neonatal outcomes. Universal screening with a GCT is a feasible and safe approach and addresses a significant health disparity gap, in that women without risk factors are screened and may be diagnosed with GDM. Given the long-term cardiometabolic implications of GDM, pregnancy diagnosis is important to allow for longer-term targeting of cardiometabolic risk factors to improve long-term health screening for type 2 diabetes and obesity.